Literature DB >> 22410580

Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.

Alberto C Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22410580     DOI： 10.1038/nrneurol.2012.40

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  The neuropsychology of Down syndrome: evidence for hippocampal dysfunction.

Authors:  Bruce F Pennington; Jennifer Moon; Jamie Edgin; Jennifer Stedron; Lynn Nadel
Journal:  Child Dev       Date:  2003 Jan-Feb

2.  Cognitive decline in Down syndrome.

Authors:  Maria Luisa Margallo-Lana; Clive Ballard; Chris Morris; David Kay; Stephen Tyrer; Brian Moore
Journal:  Arch Neurol       Date:  2003-07

Review 3.  Down syndrome and genetics - a case of linked histories.

Authors:  David Patterson; Alberto C S Costa
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

Review 4.  Alzheimer's disease in Down syndrome: neurobiology and risk.

Authors:  Warren B Zigman; Ira T Lott
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2007

5.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

Authors:  Jason Lockrow; Heather Boger; Heather Bimonte-Nelson; Ann-Charlotte Granholm
Journal:  Behav Brain Res       Date:  2010-04-02       Impact factor: 3.332

6.  Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.

Authors:  Jonah J Scott-McKean; Alberto C S Costa
Journal:  Learn Mem       Date:  2011-11-18       Impact factor: 2.460

7.  Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

Authors:  Marisa Hanney; Vee Prasher; Nicola Williams; Emma L Jones; Dag Aarsland; Anne Corbett; Dale Lawrence; Ly-Mee Yu; Stephen Tyrer; Paul T Francis; Tony Johnson; Roger Bullock; Clive Ballard
Journal:  Lancet       Date:  2012-01-10       Impact factor: 79.321

Review 8.  On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.

Authors:  Alberto C S Costa
Journal:  Dev Neurosci       Date:  2011-09-02       Impact factor: 2.984

Review 9.  Donepezil for dementia in people with Down syndrome.

Authors:  Monica Mohan; Peter K Carpenter; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
  9 in total
  5 in total

Review 1.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

2.  Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.

Authors:  R Boada; C Hutaff-Lee; A Schrader; D Weitzenkamp; T A Benke; E J Goldson; A C S Costa
Journal:  Transl Psychiatry       Date:  2012-07-17       Impact factor: 6.222

3.  Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.

Authors:  Syed Faraz Kazim; Julie Blanchard; Riccardo Bianchi; Khalid Iqbal
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

4.  Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3β signaling.

Authors:  Jillian L Shaw; Karen T Chang
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

5.  Health conditions and their impact among adolescents and young adults with Down syndrome.

Authors:  Terri J Pikora; Jenny Bourke; Katherine Bathgate; Kitty-Rose Foley; Nicholas Lennox; Helen Leonard
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.